(Q34761145)

4 August 2017

1 reference

title

AT(1)-receptor blockers: differences that matter (English)

1 reference

4 August 2017

Gradman AH

1

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Journal of Human Hypertension

4 August 2017

published in

1 reference

4 August 2017

volume

16 Suppl 3

1 reference

4 August 2017

page(s)

S9-S16

1 reference

How can the differences among AT1-receptor antagonists be explained?

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

Issues in Patient Compliance: The Search for Therapeutic Sufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesar

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001434

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001434

1 reference

Dimensions Publication ID

4 August 2017

1020745588

0 references

1 reference